Division of Neurology, Amiri Hospital, Arabian Gulf Street, Kuwait City, Kuwait.
Med Princ Pract. 2013;22(5):495-9. doi: 10.1159/000351568. Epub 2013 Jun 19.
To evaluate the outcomes of patients with multiple sclerosis (MS) who were treated with natalizumab in Kuwait.
A retrospective study using the MS registry to identify patients who were treated with natalizumab was conducted. Patients' demographics, clinical characteristics and treatment parameters were collected at baseline and last follow-up visit. Primary outcome was the proportion of relapse-free patients at the last follow-up while secondary outcomes were the change in the mean annual relapse rate, Expanded Disability Status Scale (EDSS) and the proportion of patients with magnetic resonance imaging (MRI) activity at the last follow-up visit. Forty-four patients were included in the study.
Of the 44 patients, 27 (61.4%) were females and the remaining 17 (38.6%) males. Mean age of patients and mean disease duration were 29.05 ± 7.25 and 5.71 ± 3.37 years, respectively. The mean number of natalizumab infusions was 18.14. The proportion of relapse-free patients significantly increased from 11.36 to 90.91% (p < 0.0001). The EDSS significantly improved from 4.76 to 3.15 (p < 0.0001) over the observational period. There was no significant difference between patients with EDSS <3 compared to those with EDSS ≥ 3 (p < 0.67). The proportion of patients with MRI activity was significantly reduced from 95.5 to 18.2% (p < 0.0001) at their last visit. Six patients discontinued the drug, 5 due to positive JC virus and 1 due to pregnancy.
Natalizumab induced a suppression of disease activity and was responsible for a significant improvement in disability status in highly active MS patients.
评估在科威特接受那他珠单抗治疗的多发性硬化症（MS）患者的治疗效果。
利用 MS 登记处进行回顾性研究，以确定接受那他珠单抗治疗的患者。在基线和最后一次随访时收集患者的人口统计学、临床特征和治疗参数。主要结局为最后一次随访时无复发患者的比例，次要结局为平均年复发率、扩展残疾状况量表（EDSS）和最后一次随访时存在 MRI 活动患者的比例的变化。本研究共纳入 44 例患者。
44 例患者中，27 例（61.4%）为女性，其余 17 例（38.6%）为男性。患者的平均年龄和平均病程分别为 29.05 ± 7.25 岁和 5.71 ± 3.37 年。那他珠单抗的平均输注次数为 18.14 次。无复发患者的比例从 11.36%显著增加至 90.91%（p<0.0001）。EDSS 在观察期间从 4.76 显著改善至 3.15（p<0.0001）。EDSS<3 与 EDSS≥3 的患者之间无显著差异（p<0.67）。最后一次随访时，存在 MRI 活动的患者比例从 95.5%显著降低至 18.2%（p<0.0001）。6 例患者停止使用该药物，5 例因 JC 病毒阳性，1 例因妊娠。
那他珠单抗可抑制疾病活动，使高度活跃的 MS 患者的残疾状况显著改善。
